Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 SDZNY | Healthcare | $100.76 | 11.56K | $44.88B | 69.83 | 0.98% | Moderate Buy |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| SDZNY | Sandoz Group Ltd Sponsored ADR | 100.76 | 34.35 | 51.72% |
| Name | Price | % Change | |
|---|---|---|---|
| SDZNY | $100.76 | +51.72% |
Morgan Stanley analyst Thibault Boutherin raised the firm’s price target on Sandoz (SDZNY) to CHF 60 from CHF 55 and keeps an Underweight rating on the shares. Published first on
mAbxience, a majority-owned company of Fresenius (FSNUY) with partial ownership from Insud Pharma; and Sandoz (SDZNY) announced a licensing, development, manufacturing and commercialization agreement for an emicizumab biosimilar candidate. The
Berenberg raised the firm’s price target on Sandoz (SDZNY) to CHF 72 from CHF 66 and keeps a Hold rating on the shares. Published first on TheFly – the ultimate
Erste Group analyst Hans Engel initiated coverage of Sandoz (SDZNY) with a Buy rating. The company’s product pipeline in the biosimilars segment is expanded and new markets will be tapped,
JPMorgan raised the firm’s price target on Sandoz (SDZNY) to CHF 80 from CHF 75 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate
Sandoz Group Ltd Sponsored ADR (($SDZNY)) has held its Q2 earnings call. Read on for the main highlights of the call. Sandoz Group Ltd delivered a confident earnings call, highlighting
Sandoz (SDZNY) announces several steps to further resolve the US Generic Drug Antitrust Pricing Litigation. Sandoz and its subsidiary Fougera Pharmaceuticals have entered into a settlement agreement to resolve all
Sandoz (SDZNY) confirms that the Agencia Nacional de Vigilancia Sanitaria, or ANVISA, has granted marketing authorization for Owozy, which Sandoz will commercialize in Brazil in partnership with Adalvo. Owozy was
Sandoz (SDZNY) announces that the US Food and Drug Administration, FDA, has accepted for review two Abbreviated New Drug Applications, ANDAs, for generic versions of tirzepatide. The ANDAs seek approval
Sandoz (SDZNY) confirms that the European Commission, EC, has granted marketing authorization for Bysumlog and Dazparda. The two biosimilar insulins, for injection in prefilled pens, are developed by Gan &
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| SDZNY | buy | Initiated | Aug 27, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| SDZNY | Feb 17, 2027Before Open | $44.88B | ― | ― | 0.00 | 69.83 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
